Stockscreener 앱 받기
1.47%
Altimmune Inc 주식(ALT)의 최신 뉴스
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth? - Simply Wall St
Altimmune's SWOT analysis: pemvidutide stock shows promise in obesity, NASH markets - Investing.com
Altimmune (NASDAQ:ALT) Shares Gap UpTime to Buy? - MarketBeat
Altimmune (NASDAQ:ALT) Now Covered by Stifel Nicolaus - MarketBeat
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Geode Capital Management LLC Acquires 74,194 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Barclays PLC Raises Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Down 5.9%Here's Why - MarketBeat
Altimmune Could Find A Partner For Its Phase 3 Exercise (NASDAQ:ALT) - Seeking Alpha
(ALT) Technical Data - Stock Traders Daily
Jim Cramer on Altimmune, Inc. (ALT): ‘Healthcare Is So Out Of Fashion’ - Insider Monkey
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate - Yahoo Finance
Altimmune, Inc. (NASDAQ:ALT) Shares Sold by State Street Corp - MarketBeat
Altimmune (NASDAQ:ALT) Stock Price Down 4.6%Should You Sell? - MarketBeat
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds - MSN
Altimmune (ALT) Gains on Nasdaq Biotechnology Index Inclusion - GuruFocus.com
Why Altimmune Was Such a Robustly Healthy Stock on Thursday - MSN
Altimmune (NASDAQ:ALT) Trading Up 4.7%Here's Why - MarketBeat
Altimmune joins Nasdaq Biotechnology Index - Investing.com
Altimmune Joins Nasdaq Biotechnology Index, Gears Up for Pivotal MASH Drug Trial Data in 2025 - StockTitan
(ALT) Trading Report - Stock Traders Daily
Altimmune (NASDAQ:ALT) Stock Price Down 5.1%Should You Sell? - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity stock outlook - Investing.com
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Altimmune 2025: Redefining Obesity And MASH Treatment (NASDAQ:ALT) - Seeking Alpha
Virtu Financial LLC Makes New $674,000 Investment in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Up 4.9%Still a Buy? - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune reports positive trial results for liver disease drug By Investing.com - Investing.com Nigeria
Altimmune reports positive trial results for liver disease drug - Investing.com India
Trend Tracker for (ALT) - Stock Traders Daily
Altimmune Stock Up More Than 25% in a Month: Here's Why - MSN
Portolan Capital Management LLC Sells 579,266 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook By Investing.com - Investing.com South Africa
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook - Investing.com Canada
Looking At Altimmune's Recent Unusual Options Activity - Benzinga
Altimmune shares surge on CEO's CNBC appearance By Investing.com - Investing.com Canada
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On WednesdayAltimmune (NASDAQ:ALT), Bitdeer Technologies (NASDAQ:BTDR) - Benzinga
1.07%
8.16%
자본화:
|
볼륨(24시간):